Cytolytic and Cytostatic Properties of an Anti-Human FcγRI (CD64) x Epidermal Growth Factor Bispecific Fusion Protein

Journal of Immunology

Volumn 158, Issue 2, 1997, Pages 872-879

  Goldstein, Joel ^a   Graziano, Robert F ^a   Sundarapandiyan, Karuna ^a   Somasundaram, Chezian ^a   Deo, Yashwant M ^a  

^a MEDAREX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; HYBRID PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BIOSYNTHESIS; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN BINDING;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL DIVISION; EPIDERMAL GROWTH FACTOR; FLOW CYTOMETRY; HUMANS; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS;

EID: 0031567893     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Dickson, R. B. 1990. Stimulatory and inhibitory growth factors and breast cancer. II. Oncogenes and growth factors. J. Steroid Biochem. 37:795.
2. Hollingsworth, R. E., and W. H. Lee. 1991. Tumor suppresser genes: new prospects for cancer research. J. Natl. Cancer Inst. 83:91.
3. Waterfield, M. D. 1989. Altered growth regulation in cancer. Br. Med. Bull. 45:570.
4. Modjtahedi, H., and C. Dean. 1994. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int. J. Oncol. 4:277.
5. Prigent, S. A., and N. R. Lemoine. 1992. The type I (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res. 4:1.
6. Cousens, L., T. L. Yang-Feng, Y. C. Liao, E. Chen, A. Gray, J. McGrath, P. H. Seeburg, T. A. Liberman, J. Schlessinger, U. Francke, A. Levinson, and A. Ullrich. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shows chromosomal location with neu oncogene. Science 230:1132.
7. Kraus, M. H., W. Issing, T. Miki, M. C. Popescu, and S. A. Aaronson. 1989. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor family: evidence for overexpression in a subset of human mammary tumours. Proc: Natl. Acad. Sci. USA 86:9193..
8. Plowman, G. D., J. M. Culouscou, G. S. Whitney, J. M. Green, G. W. Carlton, L. Foy, M. G. Neubauer, and M. Shoyab. 1993. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA 90:1746.
9. Owens, O. J., C. Stewart, I. Brown, and R. E. Leake. 1991. Epidermal growth factor receptors (EFGR) in human ovarian cancer. Br. J. Cancer 64:907.
10. Cowley, G., J. A. Smith, B. Gusterson, F. Hendler, and B. Ozanne. 1984. The amount of EGF receptor is elevated on squamous cell carcinomas. Cancer Cells 1:5.
11. Modjtahedi, H., and C. Dean. 1994. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int. J. Oncoil 4:277.
12. Dadparvar, S., L. Krishna, C. Miyamoto, L. W. Brady, S. J. Brown. H. Bender. W. J. Slizofski, J. Eshleman, A. Chevres, and D. Woo. 1994. Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer 73: 884.
13. + tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-ceil activation. Int. J. Cancer 55:931.
14. Liu, M. A., S. R. Nussbaum, and H. N. Eisen. 1988. Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells. Science 239:395.
15. 1H NMR. Biochemistry 30:8891.
16. Bell, G. I., N. M. Fong, M. M. Stempien, M. A. Wormsted, D. Caput, L. Ku. M. S. Urdea, L. B. Rall, and R. Sanchez-Pescador. 1986. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res. 14:8427.
17. Hollenberg, M. D., and P. Cuatrecasas. 1975. Insulin and epidermal growth factor: human fibroblast receptors related to deoxyribonucleic acid synthesis and amino acid uptake. J. Biol. Chem. 250:3845.
18. 125I-labeled epidermal growth factor to human fibroblasts. J. Biol. Chem. 250:4297.
19. Gillies, S. D., J. S. Wesolowski, and K-M. Lo. 1991. Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing cells. J. Immunol. 146:1067.
20. Fanger, M. W., L. Shen, R. F. Graziano, and P. M. Guyre. 1989. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today 10:92.
21. Unkeless, J. C., E. Scigliano, and V. H. Freeman. 1988. Structure and function of human and murine receptors for IgG. Annu. Rev. Immunol. 6:251.
22. Fanger, M. W., R. F. Graziano, L. Shen, and P. M. Guyre. 1989, FcγR in cytotoxicity exerted by mononuclear cells. Chem. Immunol. 47:214.
23. Van de Winkel, J. G. J., and C. L. Anderson. 1991. Biology of human immunoglobulin G Fc receptor. J. Leukocyte Biol. 49:511.
24. Valerius, T., R. Repp, T. P. de Wit, S. Berthold, E. Platzer, J. R. Kalden, M. Gramatzki, and J. G. van de Winkel. 1993. Involvement of the high-affinity receptor for IgG (Fc gamma RI: CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulaing factor therapy. Blood 82:931.
25. Shen, L., P. M. Guyre, and M. W. Fanger. 1987. Polymorphonuclear leukocyte function triggered through the high affinity Fc receptor for monomeric IgG. J. Immunol. 139:534.
26. Graziano, R. F. G., P. R. Tempest, P. White, T Keler, Y. Deo, H. Ghebremariam, K. Coleman, L. C. Pfefferkorn, M. W. Fanger, and P. M. Guyre. 1995. ConstrucJ tion and characterization of a humanized anti-γ-Ig receptor type I (FcγRI) monoclonal antibody. J. Immunol. 155:4996.
27. Murthy, U., A. Basu, U. Rodeck, M. Herlyn, A. H. Ross, and M. Das. 1987. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch. Biochem. Biophys. 252:549.
28. Kettleborough, C. A., J. Saldanha, V. J. Heath, C. J. Morrison, and M. M. Bendig. 1991. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 4:773.
29. Parham, P., M. J. Androlewicz, F. M. Brodski, N. J. Holmes, and J. P. Ways. 1982. Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens. J. Immunol. Methods 53:133.
30. Gill, S. C., and P. H. von Hippel. 1989. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182:319.
31. Mentzer, S. J., P. M. Guyre, S. J. Burakoff, and D. V. Faller. 1986. Spontaneous aggregation as a mechanism of human monocyte purification. Cell. Immunol. 101:312.
32. Barnes, D. W. 1982. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J. Cell Biol. 93:1.
33. MacLeod, C. L., A. Luk, J. Castagnola, M. Cronin, and J. Mendelsohn. 1986. EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells. J. Cell. Physiol. 127:175.
34. 2-phase to mitosis: a receptor-mediated phenomenon in various cells. Cancer Res. 50:7932.
35. Goldstein, J., G. R. Matsueda, and S.-Y. Shaw. 1996. A chimeric streptokinase with unexpected fibrinolytic selectivity. Thromb. Haemost. 76:429.
36. Carter, P., R. F. Kelley, M. L. Rodrigues, B. Snedecor, M. Covarrubias, M. D. Velligan, W. L. T. Wong, A. M. Rowland, C. E. Kotts, M. E. Carver, M. Yang, J. H. Bourell, H. M. Shepard, and D. Henner. 1992. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology 10:163.
37. 2 formation in Escherichia coli and for improved in vivo stability. J. Immunol. 151:6954.
38. Ely, P., P. K. Wallace, A. L. Givan, R. F. Graziano, P. M. Guyre, and M. W. Fanger. 1996. Bispecifie-armed, IFNγ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood. In press.
39. erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int. J. Cancer 60:137.
40. Kihara, A., and I. Pastan. 1995. Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin. Cancer Res. 55:71.
41. Siegall, C. B., S. S. Bacus, B. D. Cohen, G. D. Plowman, B. Mixan, D. Chase, D. M. Chin, A. Goetze, J. M. Green, I. Hellstrom, K. E. Hellstrom, and H. P. Fell. 1995. HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. J. Biol. Chem. 270:7625.
42. Chaudhary, V. K., D. J. FitzGerald, S. Adhya, and I. Pastan. 1987. Activity of a recombinant fusion protein between transforming growth factor type α and Pseudomonas toxin. Proc. Natl. Acad. Sci. USA 84:4538.
43. Heimbrook, D. C., S. M. Stirdivant, J. D. Ahern, N. L. Balishin, D. R. Patrick, G. M. Edwards, D. Defeo-Jones, D. J. FitzGerald, I. Pastan, and A. Oliff. 1990. Transforming growth factor-α-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Proc. Natl. Acad. Sci. USA 87:4697.
44. Pai, L. H., M. G. Gallo, D. J. FitzGerald, and I. Pastan. 1991. Anti-tumor activity of a transforming-growth-factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40). Cancer Res. 51:2808.
45. Gosselin, E. J., K. Wardwell, D. R. Gosselin, N. Alter, J. L. Fisher, and P. M. Guyre. 1992. Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens. J. Immunol. 149:3477.
46. Liu, C., J. Goldstein, R. F. Graziano, J. He, J. K. O'Shea, Y. Deo, and P. M. Guyre. 1996. FcγRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J. Clin. Invest. 98:2001.